Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
The New England Journal of Medicine
•
March 12, 2026
Apixaban causes less bleeding than rivaroxaban
In acute symptomatic blood clots in the legs or lungs, apixaban caused fewer clinically important bleeding events than rivaroxaban over 3 months. *Randomized trial with blinded outcome review; Level 1b (OCEBM).
- Level of evidence
- Level 1b (OCEBM)
- DocG quality score
- 8.3 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
